Search
Search Results
-
Ascites exosomal lncRNA PLADE enhances platinum sensitivity by inducing R-loops in ovarian cancer
Cisplatin resistance is a major cause of therapeutic failure in patients with high-grade serous ovarian cancer (HGSOC). Long noncoding RNAs (lncRNAs)...
-
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma
The treatment landscape for patients with advanced urothelial carcinoma continues to evolve. Enfortumab vedotin plus pembrolizumab has received Food...
-
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
Metastatic prostate cancer is a major health burden worldwide, necessitating the continuous development of effective treatment strategies. Androgen...
-
Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer
PurposeThis study aimed to assess the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus platinum versus paclitaxel...
-
Enhancing precision medicine: a nomogram for predicting platinum resistance in epithelial ovarian cancer
BackgroundThis study aimed to develop a novel nomogram that can accurately estimate platinum resistance to enhance precision medicine in epithelial...
-
Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse
BackgroundThe therapeutic effect of poly (ADP-ribose) polymerase inhibitors (PARPi) monotherapy compared with platinum-based chemotherapy, and the...
-
Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials
BackgroundPARP inhibitors (PARPi) have a well-established role in platinum-sensitive ovarian cancer (PSOC), in BRCA mutant (BRCAm), and homologous...
-
Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study
BackgroundWe previously demonstrated the applicability of the concept of “platinum sensitivity” in recurrent endometrial cancer. Although immune...
-
Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis
BackgroundTriple-negative breast cancer (TNBC), the subtype of breast cancer with the highest mortality rate, shows clinical characteristics of high...
-
ROS-mediated SRMS activation confers platinum resistance in ovarian cancer
Ovarian cancer is the leading cause of death among gynecological malignancies. Checkpoint blockade immunotherapy has so far only shown modest...
-
Insight into autophagy in platinum resistance of cancer
Platinum drugs, as a class of widely used chemotherapy agents, frequently appear in the treatment of cancer at different phrases. However, platinum...
-
Clinicopathological Nomogram for Predicting Platinum-Resistant/Refractory Epithelial Ovarian Cancer
ObjectiveTo construct a nomogram of individual risks from exploratory clinicopathological features associated with platinum-resistant/refractory...
-
Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
BackgroundProgrammed cell death protein 1 (PD-1) monoclonal antibody, pembrolizumab, is a promising drug for platinum-pretreated, recurrent or...
-
Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report
As the most lethal gynecological malignant tumor, ovarian cancer is prone to recurrence and drug resistance. Poly(ADP-ribose) polymerase inhibitors...
-
Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers
Platinum resistance is a clinical challenge in ovarian cancer. Platinating agents induce DNA damage which activate Mre11 nuclease directed DNA damage...
-
High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer
PurposeThe poor prognosis of ovarian cancer is largely due to platinum resistance. It has been demonstrated that nucleotide excision repair (NER)...
-
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
IntroductionTo evaluate the efficacy of cytoreductive surgery versus chemotherapy for the treatment of limited regional, platinum-resistant ovarian...
-
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
BackgroundSingle-agent chemotherapy with or without bevacizumab (Bev) is a standard therapy for platinum-resistant ovarian cancer (PR-OC). However,...
-
Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer
ObjectivesTo assess the clinical value of early clearance of HE4 and CA125 for platinum sensitivity and prognosis in patients with ovarian cancer.
...
-
Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration
There is emerging evidence about the predictive role of homologous recombination deficiency (HRD), but this is less defined in gastrointestinal (GI)...
